-- Fusen Pharmaceutical (HKG:1652) unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology obtained marketing approval for the Dydrogesterone Tablet from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
The drug is for the treatment of diseases and symptoms arising from endogenous progesterone deficiency.
AlphaMena on Tuesday raised the price target for Saudi conglomerate Kingdom Holding (SASE:4280) to 12.40 Saudi riyals from 12.30 riyals and affirmed its add rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
BNP Paribas on Monday initiated the coverage of British venture capital group Molten Ventures (GROW.L, GRW.IR) with an outperform rating and a price target of 6.80 pounds sterling.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Ubhar Capital Oman on Monday raised its price target for Saudi mobile telecommunications company Etihad Etisalat (SASE:7020), d/b/a Mobily, to 83.30 Saudi riyals from 79.10 riyals, while maintaining a buy rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)